I think it may be related to the FDA turning down PG testosterone patch for female sexual dysfunction is affecting the whole hormone patch sector, hopefully, the "real support, the February/March lows just under $17 will hold, since I think that NOVN has no impact from that FDA decision. The pending ruling might have been the causis belli for the recent weakness. At least the INTC mid term report seems to be putting a little fire under the SMH and some of my semi are compensating for NOVN AH weakness here. Even NVEC is getting back up in AH...